AGRX - Agile Therapeutics issues cash projection at JP Morgan healthcare conference
Agile Therapeutics (AGRX) reports estimated cash and equivalents of $54.5M as of Dec. 31, 2020, which it says will be sufficient to meet operating costs through the end of this year, presenting at the JPMorgan Healthcare Conference today.The company expects its Q4 gross revenue to be ~$1M, reflecting expectations of Twirla's initial stocking by wholesalers.Launched in Dec. 2020, Twirla is a new non-invasive contraceptive patch for transdermal system that sees a $4.1B addressable market.Stock up 1.06% premarket.
For further details see:
Agile Therapeutics issues cash projection at JP Morgan healthcare conference